News Releases Year None20242023202220212020201920182017 NuCana Announces Update for Phase 3 Biliary Tract Cancer Study Mar 02, 2022 NuCana to Participate in Two Upcoming Investor Conferences Feb 28, 2022 NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study Feb 22, 2022 NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update Nov 18, 2021 NuCana to Present at the Jefferies 2021 London Healthcare Conference Nov 10, 2021 NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors Nov 01, 2021 NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer Sep 29, 2021 NuCana Announces Four Poster Presentations at the ESMO Congress 2021 Sep 16, 2021 NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study Sep 15, 2021 NuCana to Participate in Three Upcoming Investor Conferences Sep 01, 2021 Pagination First page « first Previous page ‹ previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page next › Last page last »
NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study Feb 22, 2022
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer Sep 29, 2021
NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study Sep 15, 2021